首页> 美国卫生研究院文献>other >A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

【2h】

A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

机译：难治性子宫内膜癌患者沙利度II期试验及其与血管生成生物标志物的相关性：妇科肿瘤学研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectivesA phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of thalidomide in persistent or recurrent endometrial cancer refractory to cytotoxic chemotherapy, and to correlate angiogenesis biomarker expression with clinical outcome.

机译：目的进行一项II期临床试验，以评估沙利度胺在难治性或复发性子宫内膜癌对细胞毒性化学治疗所难治的抗肿瘤活性和不良反应中，并将血管生成生物标志物的表达与临床结果相关联。

著录项

期刊名称 other
作者
D. Scott McMeekin; Michael W. Sill; Doris Benbrook; Kathleen M. Darcy; Deborah J. Stearns-Kurosawa; Lynne Eaton; S. Diane Yamada;
展开▼
作者单位

展开▼
年(卷),期 -1(105),2
年度 -1
页码 508–516
总页数 17
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study [J] . McMeekinD.S., SillM.W., DarcyK.M., Gynecologic Oncology: An International Journal . 2012,第2期

机译：沙利度胺在难治性子宫癌肉瘤患者中的II期临床试验及其与血管生成生物标志物的相关性：妇科肿瘤小组研究
2. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. [J] . Susumu N, Sagae S, Udagawa Y, Gynecologic Oncology: An International Journal . 2008,第1期

机译：一项针对中，高危子宫内膜癌患者的盆腔放疗与以顺铂为基础的联合化疗的III期随机试验：日本妇科肿瘤小组的一项研究。
3. 920 POSTER A randomized phase III trial of pelvic radiotherapy versus cisplatinbased combined chemotherapy in patients with intermediate risk endometrial carcinoma: a Japan gynecologic oncology group study [J] . European Journal of Cancer Supplements . 2005,第2期

机译：920 POSTER在中度危险性子宫内膜癌患者中进行盆腔放疗与以顺铂为基础的联合化疗的III期随机试验：日本妇科肿瘤学小组研究
4. Iron Modified Peptides as Biomarkers of Endometrial Cancer Gynecologic Malignancies [C] . Meghan Tanner, Lindsay Schambeau, Michael Finan, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：铁改性肽作为子宫内膜癌和妇科恶性肿瘤的生物标志物
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Trial of Brivanib in Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study [O] . Matthew A. Powell, Michael W. Sill, Paul J. Goodfellow, -1

机译：Brivanib在复发或持续性子宫内膜癌的II期试验中：NRG肿瘤/妇科肿瘤小组研究
7. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study [O] . D. Scott McMeekin, Michael W. Sill, Doris Benbrook, 2007

机译：难治性子宫内膜癌患者中沙利度胺的II期试验及与血管生成生物标志物的相关性：妇科肿瘤学群体研究

A PHASE II TRIAL OF THALIDOMIDE IN PATIENTS WITH REFRACTORY ENDOMETRIAL CANCER AND CORRELATION WITH ANGIOGENESIS BIOMARKERS: A GYNECOLOGIC ONCOLOGY GROUP STUDY

摘要

著录项

相似文献

相关主题

期刊订阅